doi:10.3969/j.issn.1004-583X.2025.05.016

Abstract

CLC Number:

R574

Add to citation manager EndNote|Ris|BibTeX

URL: http://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.05.016

http://www.lchc.cn/EN/Y2025/V40/I5/468

References 29

[1]	Martínez-Vargas IU, Sánchez-Bello ME, Miguel-Rodríguez CE, et al. Myo1f has an essential role in gamma delta T intraepithelial lymphocyte adhesion and migration[J]. Front Immunol, 2023, 14:1041079.
[2]	Girard A, Vimonpatranon S, Chan A, et al. MAdCAM-1 co-stimulation combined with retinoic acid and TGF-β induces blood CD8+ T cells to adopt a gut CD101+ TRM phenotype[J]. Mucosal Immunol, 2024, 17(4):700-712.
[3]	Gordon H, Wichmann K, Lewis A, et al. Human intestinal dendritic cells can overcome retinoic acid signaling to generate proinflammatory CD4 T cells with both gut and skin homing properties[J]. J Immunol, 2024, 212(1):96-106.
[4]	Chen KY, De Giovanni M, Xu Y, et al. Inflammation switches the chemoattractant requirements for naive lymphocyte entry into lymph nodes[J]. Cell, 2024, 17:S0092-8674(24)01347-3.
[5]	Kitsou K, Kokkotis G, Rivera-Nieves J, et al. Targeting the sphingosine-1-phosphate pathway: New opportunities in inflammatory bowel disease management[J]. Drugs, 2024, 84(10):1179-1197. doi: 10.1007/s40265-024-02094-5 pmid: 39322927
[6]	Danielson SM, Lefferts AR, Norman E, et al. Myeloid cells and sphingosine-1-phosphate are required for TCRαβ intraepithelial lymphocyte recruitment to the colon epithelium[J]. J Immunol, 2024, 212(11):1843-1854. doi: 10.4049/jimmunol.2200556 pmid: 38568091
[7]	Li JK, Veeraperumal S, Aweya JJ, et al. Fucoidan modulates gut microbiota and immunity in Peyer's patches against inflammatory bowel disease[J]. Carbohydr Polym, 2024, 342:122421.
[8]	Zhang S, Li G, Qian K, et al. Exosomes derived from cancer cells relieve inflammatory bowel disease in mice[J]. J Drug Target, 2024, 32(9):1073-1085. doi: 10.1080/1061186X.2024.2369876 pmid: 38958251
[9]	Hidalgo-García L, Ruiz-Malagon AJ, Huertas F, et al. Administration of intestinal mesenchymal stromal cells reduces colitis-associated cancer in C57BL/6J mice modulating the immune response and gut dysbiosis[J]. Pharmacol Res, 2023, 195:106891.
[10]	Bressler B, Yarur A, Silverberg MS, et al. Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: Results from the EVOLVE study[J]. J Crohns Colitis, 2021, 15(10):1694-1706. doi: 10.1093/ecco-jcc/jjab058 pmid: 33786600
[11]	Visuri I, Eriksson C, Karlqvist S, et al. Long-term outcomes of vedolizumab in inflammatory bowel disease: The Swedish prospective multicentre SVEAH extension study[J]. Therap Adv Gastroenterol, 2023, 30:16:17562848231174953.
[12]	Lin WC, Tai WC, Chang CH, et al. Real-world evidence of effectiveness and safety of vedolizumab for inflammatory bowel disease in Taiwan: A prospective nationwide registry (VIOLET) study[J]. Inflamm Bowel Dis, 2023, 29(11):1730-1740.
[13]	Yan J, Ding X, Wu J, et al. Real-life effectiveness and safety of vedolizumab in moderate-to-severe ulcerative colitis: A single-center experience in Northern China[J]. Medicine (Baltimore), 2024, 103(27):e38759.
[14]	Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, et al. Real-world effectiveness of vedolizumab vs anti-TNF in biologic-naive crohn's disease patients: A 2-year propensity-score-adjusted analysis from the VEDOIBD-study[J]. Inflamm Bowel Dis, 2024, 30(5):746-756.
[15]	Sommer K, Heidbreder K, Kreiss L, et al. Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing[J]. Clin Transl Med, 2023, 13(4):e1233. doi: 10.1002/ctm2.1233 pmid: 37029786
[16]	Wiendl M, Dedden M, Liu LJ, et al. Etrolizumab-s fails to control E-cadherin-dependent co-stimulation of highly activated cytotoxic T cells[J]. Nat Commun, 2024, 15(1):1043. doi: 10.1038/s41467-024-45352-6 pmid: 38310086
[17]	Sandborn WJ, Panés J, Danese S, et al. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): A randomised, placebo-controlled, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2023, 8(1):43-55.
[18]	Zhang R, Jia Z, Piao Y. Meta-analysis of etrolizumab versus placebo in ulcerative colitis: Safety and efficacy outcomes[J]. Therap Adv Gastroenterol, 2024, 17:17562848241253685.
[19]	Ben-Horin S, Novack L, Mao R, et al. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials[J]. Gastroenterology, 2022, 162(2):482-494.
[20]	Rindi LV, Zaçe D, Braccialarghe N, et al. Drug-induced progressive multifocal leukoencephalopathy (PML): A systematic review and meta-analysis[J]. Drug Saf, 2024, 47(4):333-354.
[21]	Datta N, Johnson C, Kao D, et al. MicroRNA-based therapeutics for inflammatory disorders of the microbiota-gut-brain axis[J]. Pharmacol Res, 2023, 194:106870.
[22]	Schulze LL, Becker E, Dedden M, et al. Differential effects of ontamalimab versus vedolizumab on immune cell trafficking in intestinal inflammation and inflammatory bowel disease[J]. J Crohns Colitis, 2023, 17(11):1817-1832. doi: 10.1093/ecco-jcc/jjad088 pmid: 37208197
[23]	Vermeire S, Danese S, Sandborn WJ, et al. Efficacy and safety of the anti-mucosal addressin cell adhesion molecule-1 antibody ontamalimab in patients with moderate-to-severe ulcerative colitis or Crohn's disease[J]. J Crohns Colitis, 2024, 18(5):708-719.
[24]	Huber ME, Toy L, Schmidt MF, et al. A chemical biology toolbox targeting the intracellular binding site of CCR9: Fluorescent ligands, new drug leads and PROTACs[J]. Angew Chem Int Ed Engl, 2022, 61(12):e202116782.
[25]	Armuzzi A, Cross RK, Lichtenstein GR, et al. Cardiovascular safety of ozanimod in patients with ulcerative colitis: True north and open-label extension analyses[J]. Clin Gastroenterol Hepatol, 2024, 22(5):1067-1076.
[26]	Danese S, Panaccione R, Abreu MT, et al. Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: Interim analysis of the true north open-label extension[J]. J Crohns Colitis, 2024, 18(2):264-274.
[27]	Vermeire S, Sands BE, Peyrin-Biroulet L, et al. Impact of prior biologic or janus kinase inhibitor therapy on efficacy and safety of etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 trials[J]. J Crohns Colitis, 2024, 18(11):1780-1794.
[28]	Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies[J]. Lancet, 2023, 401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2 pmid: 36871574
[29]	D’Haens G, Dubinsky MC, Peyrin-Biroulet L, et al. Etrasimod induction therapy in moderately to severely active Crohn’s disease: Results from a phase 2, randomised, double-blind substudy[abstract no. P632][J]. J Crohns Colitis, 2023, 17(Suppl_1):i764-765.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 29

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(11): 1035-1039.
[2]	Gu Dandan, Zhou Xiaoxian, Wang Jingxian, Wu Chunxiao. Rectal cap polyposis: A case report and literature review [J]. Clinical Focus, 2024, 39(9): 828-832.
[3]	Chen Xiaotian, Huo Lijuan. Predictive value of serum total bilirubin, neutrophil-to-total bilirubin ratio in evaluating the condition of ulcerative colitis [J]. Clinical Focus, 2024, 39(7): 603-611.
[4]	Ren Huaijing, Tao Jianan, Ma Zhenqi, Wang Xuehong. Colonic telangiectasia combined with bleeding: A case report and literature review [J]. Clinical Focus, 2024, 39(2): 155-159.
[5]	Chen Xiaotian, Huo Lijuan. Meta-analysis of clinical significance of serum total bilirubin level in inflammatory bowel disease [J]. Clinical Focus, 2023, 38(8): 677-685.
[6]	Li Lifang, Wang Hongyan. Respiratory Whipple's disease: A case report and literature review [J]. Clinical Focus, 2022, 37(12): 1127-1131.
[7]	Zhang Xiumin, Zhao Changdong, Li Xue, Lu Xuefeng, Liu Weizhong, Wang Shufang. Relationship between indoleamine 2, 3-dioxygenase and peripheral blood CD4 + in patients with ulcerative colitis [J]. Clinical Focus, 2021, 36(8): 696-698.
[8]	Song Yiran, Liang Xiaonan, Li Chenyang, Zhang Xiaolan. Interpretation on Chinese Expert Consensus of Irritable Bowel Syndrome in 2020 [J]. Clinical Focus, 2021, 36(7): 628-631.
[9]	. [J]. Clinical Focus, 2021, 36(5): 467-470.
[10]	Wang Tingting, Wang Liangzhi. Expression and clinical significance of apolipoprotein M in inflammatory bowel disease [J]. Clinical Focus, 2016, 31(1): 53-55.
[11]	Guo Wenbin,Sun Ximing. Clinical effect of pernasal catheter in adhesive intestinal obstruction [J]. Clinical Focus, 2016, 31(1): 85-87.
[12]	. [J]. Clinical Focus, 2015, 30(9): 1056-1059.
[13]	. @@ [J]. Clinical Focus, 2014, 29(12): 1401-0.
[14]	. @@ [J]. Clinical Focus, 2014, 29(12): 1429-1431.
[15]	ZHENG Xiu-li;FU Xue-song;WANG Yu-gang;ZHANG Yan-hua;ZHAO Xia;LI Hong-yin. Effect of otilonium bromide combined with probiotics for diarrhea-predominant irritable bowel syndrome [J]. Clinical Focus, 2014, 29(10): 1168-1170.